Skip to main content

ColoSense® offered by Labcorp*

Noninvasive CRC screening designed for completion, follow-through, and reliable detection
Provider on the phone while looking at a computer screen

ColoSense®: Innovative screening with real-world practicality

ColoSense is the first FDA-approved**, multi-target stool-based colorectal cancer (CRC) screening test using innovative RNA technology for reliable CRC detection in average-risk adults aged 45 and older.¹ It combines high performance in detecting CRC and advanced adenomas with a simplified at-home collection process, helping overcome barriers like colonoscopy hesitancy and complexity of other options. ColoSense is integrated into EHRs via Labcorp Link® for seamless ordering.

RNA technology: Advancing CRC screening

ColoSense uses a multi-target stool RNA (mt-sRNA) approach to detect colorectal neoplasia-associated biomarkers alongside occult hemoglobin in stool.1

RNA reflects real-time gene expression, allowing detection of biologic activity associated with CRC and advanced adenomas.2

This enables2:

  • Detection of molecular signals linked to CRC and advanced adenomas

  • A comprehensive biological view of disease activity

  • Strong performance for reliable detection

Clinical performance highlights1

0 sensitivity for CRC overall (100% stage I CRC sensitivity)***
0 specificity (clean colonoscopy)
0 sensitivity for advanced adenomas

  • Validated in a large prospective clinical study in average-risk patients

  • Detection is consistent across age groups, including adults 45-49


***12/12 patients (100%, 95% confidence interval, 74%-100%)


A simpler at-home collection experience that patients are more likely to complete

Patients cite discomfort, including the collection process, as a top barrier for CRC screening.3 ColoSense is designed to help reduce this friction with a simplified method that eliminates the need for stool sample manipulation, helping more patients complete screening once it’s ordered.

At-home CRC screening in three simple steps: 

Provider orders the test

Number 1 icon

Patient collects the sample using a kit shipped to their home

Number 2 Icon

Patient mails it back using prepaid packaging

Number 3 Icon


Results are delivered to the ordering provider and made available to patients through the secure Labcorp Patient Portal.

ColoSense kit is designed for a clean, simple, and patient-friendly collection experience
 

Image of the ColoSense kit and its containments

CRC screening aligned with real-world primary care

Screening doesn’t end with ordering a test; it requires follow-through. ColoSense integrates into existing practice infrastructure, enabling providers to move through the screening continuum with greater consistency.

Patient engagement and navigation

24/7 support, education, personalized reminders for test completion and rescreening (every three years), and clear guidance on next steps for positive results, including assistance with follow-through to colonoscopy4† 

Labcorp Insight Analytics®

Population-level visibility into CRC screening gaps 

Labcorp Diagnostic Assistant®

Patient-level tracking of specimen status, results, and trends

EHR integration via Labcorp Link®

Seamless ordering and reporting

Together, these capabilities support the full CRC screening pathway, from initial recommendation to test completion and diagnostic follow-up.

Take the next step

See how Labcorp can help improve CRC screening completion and support earlier detection in your practice.

 

References

  1. ColoSense® Clinician Brochure. St. Louis, MO: Geneoscopy, Inc.
  2. National Human Genome Research Institute. Gene expression. Genome.gov. Updated June 26, 2023. https://www.genome.gov/genetics-glossary/Gene-Expression
  3. Count on you, 2025 edition
  4.  Wolf AMD, Hoffman RM, Walter LC, et al. Colorectal cancer screening: an update to the American Cancer Society guideline, 2026. CA Cancer J Clin. 2026; e70083. doi:10.3322/caac.70083

*Labcorp offers ColoSense through a commercial collaboration with Geneoscopy, enabling health care customers to conveniently order through Labcorp as part of their comprehensive screening programs.

**ColoSense was granted Breakthrough Device designation. It is the only RNA-based stool test with this distinction, acknowledging its innovative approach to CRC detection. 

†Provider opt-in required

ColoSense is a registered trademark of Geneoscopy. 

At-home colon cancer screening made easy

ColoSense is an FDA-approved**, non-invasive at-home screening test for adults aged 45+ who are at average risk for colorectal cancer (CRC). Created with your experience in mind, it features a simplified collection process that helps minimize sample handling compared with other at-home stool-based tests. Recommended every three years, ColoSense offers convenient at‑home sample collection along with end‑to‑end screening support, including patient outreach.

The test supports disease detection by using RNA technology to look at biomarkers associated with colorectal cancer and advanced adenomas (precancerous lesions). These specific biomarkers are genetic signals in the body that change when cancer or precancer is present.

ColoSense is an FDA-approved screening test that can detect:

  • Colorectal cancer

  • Advanced adenomas (precancerous lesions) that could develop into cancer


The most effective screening is the one you complete

ColoSense combines trusted science with a simpler experience designed to help you follow through.

Accuracy you can feel confident in

0 sensitivity for detecting colorectal cancer¹

Screening that works for you

0 of people who have never screened for CRC prefer to start with an at-home test²

An easier at-home screening experience

Many people say colorectal cancer screening feels uncomfortable or complicated, especially when it involves handling a stool sample. ColoSense is designed to make this process easier. With a simpler collection method that removes the need to handle your sample directly, it helps reduce the hassle so you can complete your screening with more confidence and less stress.

At-home CRC screening in just three simple steps
 

Your provider orders the test

Your kit is shipped directly to your home

Number 1 icon

Collect your sample

The kit is designed for a clean, straightforward collection experience

Number 2 Icon

Send it back

Use the prepaid package to return your sample.

Your result is shared with your provider and available through the MyLabcorp™ app or online at MyLabcorp.com

Number 3 Icon

Colorectal cancer by the numbers

0 people in the U.S. are diagnosed with CRC each year³
0 of CRC cases in adults under 50 are advanced stage⁴
0 survival rate among those diagnosed early (before cancer has spread)⁵

Colon cancer screening: Early detection saves lives, but many people still put it off

CRC remains one of the most common, yet preventable, cancers in the U.S.6 With the recent rise in cases among adults under 50, more people are paying attention and seeking out information about screening and prevention.

CRC can be especially challenging because many people don’t experience symptoms in the early stages. This means you may feel completely healthy and still be at risk. Add in busy schedules and concerns about test preparation, and it’s easy to see why many people delay screening. But screening doesn’t have to feel overwhelming.

For average-risk adults, screening is recommended starting at age 45, even if you feel fine. Regular screening can detect cancer early, when it's most treatable, and it can also identify advanced adenomas (precancerous lesions) before they develop into cancer.

You don’t have to navigate your colorectal cancer screening options alone. Studies show you are much more likely to follow through with screening after discussing it with your healthcare provider.7 Together, you can choose the right approach for your specific needs.

Start the conversation today by asking your provider if ColoSense® offered by Labcorp is right for you. Keep in mind that if you have a personal or family history of colorectal cancer, or other specific risk factors, your provider may recommend an alternative screening method, such as a colonoscopy.

Frequently asked questions

Start the conversation today by asking your provider if ColoSense® offered by Labcorp is right for you.

Keep in mind that if you have a personal or family history of colorectal cancer, or other specific risk factors, your provider may recommend an alternative screening method, such as a colonoscopy.

References

  1. Geneoscopy. Geneoscopy’s new FDA-approved stool collection method simplifies at-home colorectal cancer screening. Geneoscopy. Accessed June 2, 2026.
  2. 2025 Labcorp Colon Cancer Survey.
  3. American Cancer Society. Key statistics for colorectal cancer. American Cancer Society. Accessed June 2, 2026. https://cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html
  4. Siegel, R. L., Wagle, N.S., & Jemal, A. (2026). Leading Cancer Deaths in People Younger Than 50 Years. JAMA, 335(7), 632-634. https://doi.org/10/1001/jama.2025.25467
  5. American Cancer Society. Colorectal cancer survival rates. American Cancer Society. Accessed June 2, 2026. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
  6. Centers for Disease Control and Prevention. Colorectal cancer statistics. Centers for Disease Control and Prevention. Accessed June 2, 2026. https://www.cdc.gov/colorectal-cancer/statistics/index.html
  7. American Cancer Society. American Cancer Society recommendations for colorectal cancer early detection. American Cancer Society. Accessed June 2, 2026. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html  

*Labcorp offers ColoSense through a commercial collaboration with Geneoscopy, enabling healthcare customers to conveniently order through Labcorp as part of their comprehensive screening programs.

**ColoSense was granted Breakthrough Device designation. It is the only RNA-based stool test with this distinction, acknowledging its innovative approach to CRC detection. 

Indications and Important Risk Information

ColoSense is intended to screen adults aged 45 years or older who are at average risk for developing CRC. Do not use ColoSense if you have personal history of CRC or other related cancers, have inflammatory bowel disease or certain hereditary syndromes, received a positive result on another CRC screening method within the last six months or 12 months for fecal occult blood test or fecal immunochemical test. ColoSense is not a replacement for colonoscopy in high-risk individuals. False positives and false negatives can occur. Please see full Important Risk Information at ColoSense.com/risk-information 

ColoSense is a registered trademark of Geneoscopy. ColoSense offered by Labcorp is available through a commercial collaboration with Geneoscopy allowing expanded access for patients to colorectal cancer screening solutions nationwide.